Alhaj-Suliman and colleagues investigated the combined use of the ciprofloxacin derivative CIP2b and paclitaxel (PTX) to combat resistance in type-II endometrial cancer associated with p53 mutations and MDR1 overexpression. This evidence concerns the gene TP53 and endometrial cancer.